VICORE PHARMA AB

Webcast – CTA for the treatment of COVID-19 with C21, March 2020

C21 IN COVID-19



COVID-19 is an emerging pandemic for which we have no cure

vicore pharma

C21 IN COVID-19

RAS in COVID-19 - Background



C21 IN COVID-19 - RENIN-ANGIOTENSIN SYSTEM (RAS)



There is a balance between pro-inflammatory AT1R and anti-inflammatory AT2R

vicore pharma

C21 IN COVID-19 - THE CoV-2 CREATES AN IMBALANCE IN RAS



C21, an AT2R agonist, may bypass the RAS imbalance to prevent the cytokine storm

vicore pharma

C21 IN COVID-19 - MODE OF ACTION

C21 is a first in class small molecule stimulating the angiotensin type 2 receptor (AT2R)

Angiotensin II has 2 receptors with opposite actions



In COVID 19, ACE2 is hi-jacked resulting in increased AT1R activation



It is hoped that, by stimulating AT2R directly, C21 will counteract the ANG II effects



C21 may bypass ACE2 and be directly anti-inflammatory through AT2R

C21 IN COVID-19

Phase II PoC study



C21 IN COVID-19 - SELECTION OF PATIENT POPULATION



C21 IN COVID-19 - STUDY DESIGN



A randomized, double-blind, placebo-controlled phase II trial investigating the efficacy of C21 on oxygen saturation and outcome in subjects with moderate COVID-19 treated with oxygen supply



- Patients will be monitored for oxygen saturation, which determines outcome – recovery or disease progression with need for assisted ventilation
- The study will also measure infection parameters and biomarkers
- We will initially have one site and anticipate to start in approximately 4 weeks with completion of the clinical part in 3 months

The primary endpoint is to prevent disease progression

vicore pharma

C21 IN COVID19

Summary



C21 IN COVID-19 – SUMMARY



- **The COVID-19 is an emerging pandemic for which there is currently no cure**
- **The virus hi-jacks the enzyme ACE2 to infect the alveolar cells**
- **ACE2 normally brakes down pro-inflammatory ANGII to molecules that are protective via AT2R**
- **Binding of virus incapacitates ACE2 leading to an imbalance in the RAS system, promoting inflammation and development of ARDS**
- **C21, an AT2R agonist, is independent of ACE2 and may therefore prevent the lung damaging inflammation in COVID-19**
- **The company has generated preclinical data to support the concept**
- **A rolling CTA submission has been initiated today and Vicore anticipates to start enrolling patients in 4 weeks**

vicore pharma